Cargando…

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis

BACKGROUND: We have previously shown that 15 urinary biomarkers (of 129 tested by Luminex), discriminate between active Lupus Nephritis (ALN) and non-LN patients. The aim of this study was to evaluate the ability of these 15 previously-identified urinary biomarkers to predict treatment responses to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whittall-Garcia, Laura, Goliad, Kirubel, Kim, Michael, Bonilla, Dennisse, Gladman, Dafna, Urowitz, Murray, Fortin, Paul R., Atenafu, Eshetu G., Touma, Zahi, Wither, Joan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196040/ https://www.ncbi.nlm.nih.gov/pubmed/35711439 http://dx.doi.org/10.3389/fimmu.2022.889931

Ejemplares similares

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus
por: Mai, Lloyd, et al.
Publicado: (2021)

Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms
por: Wither, Joan E., et al.
Publicado: (2018)

Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis
por: Kim, Sonya T., et al.
Publicado: (2023)

Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus
por: Medina-Rosas, Jorge, et al.
Publicado: (2015)

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease
por: Al Rayes, Hanan, et al.
Publicado: (2017)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50
por: Touma, Z, et al.
Publicado: (2012)

A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis
por: Landolt-Marticorena, Carolina, et al.
Publicado: (2016)

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments
por: Touma, Zahi, et al.
Publicado: (2017)

Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort
por: Fung, William A., et al.
Publicado: (2017)

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies
por: Tselios, Konstantinos, et al.
Publicado: (2016)

Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus
por: Yuen, Kimberley, et al.
Publicado: (2021)

Insight into intraindividual variability across neuropsychological tests and its association with cognitive dysfunction in patients with lupus
por: He, Jennifer Wei, et al.
Publicado: (2021)

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
por: Tselios, Konstantinos, et al.
Publicado: (2021)

Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematous
por: Moazzami, Mitra, et al.
Publicado: (2021)

Altered Balance of Pro-Inflammatory Immune Cells to T Regulatory Cells Differentiates Symptomatic From Asymptomatic Individuals With Anti-Nuclear Antibodies
por: Gupta, Rashi, et al.
Publicado: (2022)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Urinary biomarkers in lupus nephritis
por: Aragón, Cristian C., et al.
Publicado: (2020)

International validation of a urinary biomarker panel for identification of active lupus nephritis in children
por: Smith, Eve Mary Dorothy, et al.
Publicado: (2016)

Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study
por: Nikpour, Mandana, et al.
Publicado: (2010)

Herpes zoster in SLE: prevalence, incidence and risk factors
por: Kwan, Andrew, et al.
Publicado: (2022)

Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study
por: Nikpour, Mandana, et al.
Publicado: (2011)

Rethinking Lupus Nephritis Classification on a Molecular Level
por: Almaani, Salem, et al.
Publicado: (2019)

The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients
por: Liu, Li, et al.
Publicado: (2020)

Increased excretion of urinary podocytes in lupus nephritis
por: Bollain-y-Goytia, J. J., et al.
Publicado: (2011)

Association of Urinary Lipocalin-2 with Lupus Nephritis
por: Sharifipour, Farzaneh, et al.
Publicado: (2013)

Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis
por: Romick-Rosendale, Lindsey E, et al.
Publicado: (2011)

Stability of novel urinary biomarkers used for lupus nephritis
por: Cody, Ellen M., et al.
Publicado: (2022)

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
por: Al Rayes, Hanan, et al.
Publicado: (2014)

Can measuring urinary biomarkers improve the management of lupus nephritis?
por: Rahman, Anisur
Publicado: (2012)

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
por: Williams-Hall, Rebecca, et al.
Publicado: (2022)

Hydralazine-Induced Isolated Lupus Nephritis
por: Khan, Naseer, et al.
Publicado: (2020)

Urinary VCAM-1 as a biomarker of lupus nephritis disease activity
por: Smith, Eve, et al.
Publicado: (2014)

Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis
por: Mok, Chi Chiu, et al.
Publicado: (2018)

Urinary Long Non-Coding RNA Levels as Biomarkers of Lupus Nephritis
por: Szeto, Cheuk-Chun, et al.
Publicado: (2023)

Urinary balantidiasis in a patient with systemic lupus erythematosus and lupus nephritis: a case report
por: Martviset, Pongsakorn, et al.
Publicado: (2020)

The Value of a Panel of Autoantibodies for Predicting the Activity of Lupus Nephritis at Time of Renal Biopsy
por: Moroni, Gabriella, et al.
Publicado: (2015)

Next generation sequencing identifies miRNA-based biomarker panel for lupus nephritis
por: Su, Yu-Jih, et al.
Publicado: (2018)

Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis
por: Wither, Joan, et al.
Publicado: (2017)

Measuring eosinophiluria, urinary eosinophil cationic protein and urinary interleukin-5 in patients with Lupus Nephritis
por: Brito, Tereza Neuma Souza, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5h1rt75hvg1q4nmed0e2ldp3gj